West Pharmaceutical Services, I (WST) Stock Analysis
Recovery setup
Healthcare · Medical Instruments & Supplies
Hold if already holding. Not a fresh buy at $295.36, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: sales outside the U.S. (56.7%); Thin upside margin: 3.0%.
West Pharmaceutical Services designs and manufactures containment and delivery systems for injectable drugs via two segments: Proprietary Products (packaging, delivery devices) and Contract-Manufactured Products. Top 10 customers account for 47.6% of 2025 net sales; one customer... Read more
Hold if already holding. Not a fresh buy at $295.36, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: sales outside the U.S. (56.7%); Thin upside margin: 3.0%. Chart setup: Death cross but MACD improving, RSI 71. Maintain position. Not compelling to add more. Score 6.0/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.60, earnings proximity 84d clear, semi cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicsales outside the U.S.57%10-K Item 1: 'Sales outside of the U.S. accounted for 56.7% of our consolidated net sales in 2025'
- MEDIUMCustomertop-10 customers48%10-K Item 1: 'Our ten largest customers accounted for 47.6% of our consolidated net sales in 2025'
- MEDIUMCustomerone customer (15.8% of net sales)16%10-K Item 1: 'one of these customers individually accounted for more than 10% of consolidated net sales, at 15.8% or $485.9 million'
- MEDIUMSuppliersingle-source suppliers for critical raw materials10-K Item 1: 'we rely on single-source suppliers for certain critical raw materials'
Material Events(8-K, last 90d)
- 2026-03-09Item 5.02MEDIUMPresident, CEO and Board Chair Eric M. Green announced intent to retire once successor is hired (expected 2H 2026). Board engaged executive recruiting firm; no successor named. Green to remain in role until transition occurs.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·1 ceiling hit
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $295.36, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: sales outside the U.S. (56.7%); Thin upside margin: 3.0%. Chart setup: Death cross but MACD improving, RSI 71. Maintain position. Not compelling to add more. Target $304.37 (+3.1%), stop $274.68 (−7.5%), A.R:R 0.2:1. Score 6.0/10, moderate confidence.
Take-profit target: $304.37 (+3.1% upside). Target $304.37 (+3.1%), stop $274.68 (−7.5%), A.R:R 0.2:1. Stop-loss: $274.68.
Concentration risk — Geographic: sales outside the U.S. (56.7%); Thin upside margin: 3.0%; Expensive valuation.
West Pharmaceutical Services, I trades at a P/E of 39.5 (forward 30.9). TrendMatrix value score: 3.7/10. Verdict: Hold.
23 analysts cover WST with a consensus score of 4.0/5. Average price target: $350.
What does West Pharmaceutical Services, I do?West Pharmaceutical Services designs and manufactures containment and delivery systems for injectable drugs via two...
West Pharmaceutical Services designs and manufactures containment and delivery systems for injectable drugs via two segments: Proprietary Products (packaging, delivery devices) and Contract-Manufactured Products. Top 10 customers account for 47.6% of 2025 net sales; one customer at 15.8% ($485.9M). International sales are 56.7% of net sales.